What are the key takeaways from this The Life Science Rundown episode?

Key insights include: **Inspection Room Infrastructure:** Structure inspections across four dedicated rooms: a front room with quality and technical leads, a backroom staffed with IT-fluent document retrievers connected via Teams or Zoom chat for parallel request processing, a document review room with department SMEs, and a preparation room where experienced staff role-play inspector conversations with employees before they enter.; **Leadership Demeanor as Risk Control:** A leader's visible calm directly regulates team anxiety during inspections. Operators and analysts know their jobs better than anyone, so leaders should frame inspections as an opportunity to demonstrate competence, not a threat. Equally, coach employees to answer only what is asked — volunteering excess information creates unintended threads for inspectors to pull.; **Remediation Prioritization Framework:** When managing a large observation backlog alongside ongoing manufacturing, sequence work by regulatory urgency: stability samples first, prefill or in-process tests second, and discretionary studies last. Communicate trade-offs explicitly to internal customers. Use color-coded project tracking to build team momentum by closing easier observations before tackling complex, multi-department findings.

What did Jeff Hines discuss on The Life Science Rundown?

Jeff Hines, VP of Quality at Karuna Medical with 37 years of pharmaceutical industry experience including 30 years at Eli Lilly, outlines leadership strategies for navigating FDA inspections across PAI, routine, and for-cause scenarios, covering inspection infrastructure, remediation execution, employee morale, and building lasting compliance culture. Key topics include: **Inspection Room Infrastructure:** Structure inspections across four dedicated rooms: a front room with quality and technical leads, a backroom staffed with IT-fluent document retrievers connected via Teams or Zoom chat for parallel request processing, a document review room with department SMEs, and a preparation room where experienced staff role-play inspector conversations with employees before they enter.; **Leadership Demeanor as Risk Control:** A leader's visible calm directly regulates team anxiety during inspections. Operators and analysts know their jobs better than anyone, so leaders should frame inspections as an opportunity to demonstrate competence, not a threat. Equally, coach employees to answer only what is asked — volunteering excess information creates unintended threads for inspectors to pull..

How long is this episode of The Life Science Rundown?

This episode is 52 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

The Life Science Rundown

A Playbook for FDA Inspections and Remediation with Jeff Hines

October 16, 2025

52 min episode · 2 min read

Jeff Hines

Episode

52 min

Read time

2 min

Topics

Productivity, Leadership, Software Development

AI-Generated Summary

Published Mar 16, 2026

Key Takeaways

✓Inspection Room Infrastructure: Structure inspections across four dedicated rooms: a front room with quality and technical leads, a backroom staffed with IT-fluent document retrievers connected via Teams or Zoom chat for parallel request processing, a document review room with department SMEs, and a preparation room where experienced staff role-play inspector conversations with employees before they enter.
✓Leadership Demeanor as Risk Control: A leader's visible calm directly regulates team anxiety during inspections. Operators and analysts know their jobs better than anyone, so leaders should frame inspections as an opportunity to demonstrate competence, not a threat. Equally, coach employees to answer only what is asked — volunteering excess information creates unintended threads for inspectors to pull.
✓Remediation Prioritization Framework: When managing a large observation backlog alongside ongoing manufacturing, sequence work by regulatory urgency: stability samples first, prefill or in-process tests second, and discretionary studies last. Communicate trade-offs explicitly to internal customers. Use color-coded project tracking to build team momentum by closing easier observations before tackling complex, multi-department findings.
✓Data Integrity Gap Mapping: When addressing data integrity observations, create step-by-step data flow maps tracing every action from test initiation to final result, identifying each point where an analyst interfaces with the IT system. This process, applied at both laboratory and manufacturing levels, surfaces unknown vulnerabilities — such as audit trail manipulation capabilities — that standard SOP validation procedures routinely miss.
✓Compliance Culture Maintenance: Prevent repeat findings by institutionalizing annual GMP update training that reviews observations from both internal sites and external companies, tracks regulatory shifts, and updates procedures accordingly. Treat quality as a value center rather than a cost center. Invest in conference attendance and regulatory publications, and build bench depth so inspection readiness does not depend on a single experienced individual.

What It Covers

Jeff Hines, VP of Quality at Karuna Medical with 37 years of pharmaceutical industry experience including 30 years at Eli Lilly, outlines leadership strategies for navigating FDA inspections across PAI, routine, and for-cause scenarios, covering inspection infrastructure, remediation execution, employee morale, and building lasting compliance culture.

Key Questions Answered

•Inspection Room Infrastructure: Structure inspections across four dedicated rooms: a front room with quality and technical leads, a backroom staffed with IT-fluent document retrievers connected via Teams or Zoom chat for parallel request processing, a document review room with department SMEs, and a preparation room where experienced staff role-play inspector conversations with employees before they enter.
•Leadership Demeanor as Risk Control: A leader's visible calm directly regulates team anxiety during inspections. Operators and analysts know their jobs better than anyone, so leaders should frame inspections as an opportunity to demonstrate competence, not a threat. Equally, coach employees to answer only what is asked — volunteering excess information creates unintended threads for inspectors to pull.
•Remediation Prioritization Framework: When managing a large observation backlog alongside ongoing manufacturing, sequence work by regulatory urgency: stability samples first, prefill or in-process tests second, and discretionary studies last. Communicate trade-offs explicitly to internal customers. Use color-coded project tracking to build team momentum by closing easier observations before tackling complex, multi-department findings.
•Data Integrity Gap Mapping: When addressing data integrity observations, create step-by-step data flow maps tracing every action from test initiation to final result, identifying each point where an analyst interfaces with the IT system. This process, applied at both laboratory and manufacturing levels, surfaces unknown vulnerabilities — such as audit trail manipulation capabilities — that standard SOP validation procedures routinely miss.
•Compliance Culture Maintenance: Prevent repeat findings by institutionalizing annual GMP update training that reviews observations from both internal sites and external companies, tracks regulatory shifts, and updates procedures accordingly. Treat quality as a value center rather than a cost center. Invest in conference attendance and regulatory publications, and build bench depth so inspection readiness does not depend on a single experienced individual.

Notable Moment

Hines describes accepting an FDA observation he strongly disagreed with — a lab had tightened statistical controls to three injections at 1.1% RSD instead of six at 2%, demonstrating equal or higher confidence. He reverted to the standard method anyway, concluding some battles cost more than the compliance inconvenience they solve.

Know someone who'd find this useful?

Episode Transcript

Hello, everyone. Welcome to the life science rundown. This is Nicholas Catman with the FDA group. Before we jump into our discussion for today, just a little bit about the FDA group. We help life science companies in the areas of quality assurance, regulatory affairs, clinical operations, commissioning, qualification, and validation, as well as pharmacovigilance. We offer three different engagement models, which are consulting, staff augmentation, and full time employer recruitment. So if you find yourself in need, just head over to the fdagroup.com to check us out and get in touch. So today, I'm speaking with Jeff Hines. Hi, Jeff. How are you? Good, Nick. Thanks for having me on. Absolutely. Really appreciate you joining me today. So be before we jump into the topic, would you please introduce yourself? Yeah. So I've been in the industry in the pharmaceutical industry for the better part of thirty seven years now. I'm currently vice president of quality at a company called Karuna Medical. But before that, I had experience, working with Baxter Healthcare. I spent thirty years of my career with Eli Lilly and Company, and I kinda had a foreshadowing of, what I was gonna get involved with early in my career. In the last few years, I've done a lot of inspection readiness, inspection response leading, inspection remediation, that kind of thing. It was interesting when I worked for Baxter one day, I came in and I went to my cube. I was a bench chemist at the time, and, there was a large document on my desk with a Post it note on it that said, see me. Read this and see me for my boss. And what I got to read was the 1989, FDA 40 '3 that was written, in the dry products manufacturing plant in Eli Lilly and Company. And, it was a big document, so it took me a bit to read. I think there were over a 100 observations. And, what I read terrified me. And I I basically, I was like, you know what? I wish ill on nobody, but I'm glad they went to Lily before they came to Baxter because we would have had absolutely received many of those same observations from them. It was highly, you know, dictated towards data documentation, lack of method validation, you know, like reports and things like that, lack of focus protocols on retest, resample opportunities. Right? So we got busy for several months and began, you know, writing reports and doing studies and and things like that. Well, flash forward a few years later, my wife and I decided to relocate, you know, back, you know, towards, where my parents lived. And we were lucky enough to get jobs at at Eli Lilly. And one of the first, activities that I had, I was hired into the Qualia area, again, doing some bench chemistry. And I I one of my first assignments was to actually execute a validation study for one of …

Get the full transcript (7,539 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all The Life Science Rundown transcripts →